TrialWorld journal of stem cells2025

Multiroute administration of Wharton's jelly mesenchymal stem cells in chronic complete spinal cord injury: A phase I safety and feasibility study.

Necati Kaplan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.